{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:52:18Z","timestamp":1790052738878,"version":"4.0.1"},"reference-count":90,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5551\/jat.12849","type":"journal-article","created":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T22:43:02Z","timestamp":1351118582000},"page":"123-133","source":"Crossref","is-referenced-by-count":84,"title":["Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis"],"prefix":"10.5551","volume":"20","author":[{"given":"William F","family":"Keane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) McCullough PA: Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hyperten, 2004; 13: 591-600","DOI":"10.1097\/00041552-200411000-00003"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.07.051"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) McCullough PA, Verrill TA: Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med, 2010; 122: 25-34","DOI":"10.3810\/pgm.2010.03.2119"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002; 39: S1-266","DOI":"10.1016\/S0272-6386(02)70054-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Levey AS, Stevens LA, Coresh J: Conceptual model of CKD: applications and implications. Am J Kidney Dis, 2009; 53: S4-16","DOI":"10.1053\/j.ajkd.2008.07.048"},{"key":"6","unstructured":"6) United States Renal Data System (USRDS). Annual Data Report on ESRD & Chronic Kidney Disease (CKD) in the United States. http: \/\/www.usrds.org\/atlas.aspx. 2011"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150: 604-612","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, 2010; 375: 2073-2081","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305","DOI":"10.1056\/NEJMoa041031"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA, 2007; 298: 2038-2047","DOI":"10.1001\/jama.298.17.2038"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.483"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004030203"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004080656"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y: Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol, 2011; 6: 1112-1120","DOI":"10.2215\/CJN.09961110"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Funck-Brentano C, Poldermans D, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL: ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32: 1769-1818","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04320709"},{"key":"17","unstructured":"17) National Kidney Foundation: K\/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis, 2003; 41(suppl 3): S1-S92"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.04.024"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391203"},{"key":"20","unstructured":"20) Kasiske BL: Cardiovascular disease after renal transplantation. Semin Nephrol, 2000; 20: 176-187"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. Transplantation, 2001; 72: S5-S8 citation=22) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis, 2007; 49: S12-154","DOI":"10.1053\/j.ajkd.2006.12.005"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.03.019"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis, 2006; 47: S11-145","DOI":"10.1053\/j.ajkd.2006.03.010"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2008.10.011"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26) Vaziri ND, Norris K: Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease. Blood Purif, 2011; 31: 189-196","DOI":"10.1159\/000321845"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27) Stegmayr B, Olivecrona T, Olivecrona G: Lipoprotein lipase disturbances induced by uremia and hemodialysis. Semin Dial, 2009; 22: 442-444","DOI":"10.1111\/j.1525-139X.2009.00597.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28) Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol, 2006; 290: F262-F272","DOI":"10.1152\/ajprenal.00099.2005"},{"key":"28","unstructured":"29) Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl, 200299-102"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139X.2002.00083.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) Harper CR, Jacobson TA: Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol, 2008; 51: 2375-2384","DOI":"10.1016\/j.jacc.2008.03.025"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1159\/000302712"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33) Keane WF, Tomassini JE, Neff DR: Lipid abnormalities in patients with chronic kidney disease. Contrib Nephrol, 2011; 171: 135-142","DOI":"10.1159\/000327317"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34) Kaysen GA: New Insights into Lipid Metabolism in Chronic Kidney Disease: What Are the Practical Implications? Blood Purif, 2009; 27: 86-91","DOI":"10.1159\/000167015"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2006.01168.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36) Kruit JK, Groen AK, van Berkel TJ, Kuipers F: Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol, 2006; 12: 6429-6439","DOI":"10.3748\/wjg.v12.i40.6429"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37) Vaziri ND, Liang KH: Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int, 1997; 51: 913-919","DOI":"10.1038\/ki.1997.129"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38) Redgrave TG: Chylomicron metabolism. Biochem Soc Trans, 2004; 32: 79-82","DOI":"10.1042\/bst0320079"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200306000-00002"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.01.023"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41) Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H: Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol, 2005; 25: 2615-2622","DOI":"10.1161\/01.ATV.0000188555.60475.c2"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42) Vaziri ND, Liang KH: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int, 1996; 50: 1928-1935","DOI":"10.1038\/ki.1996.515"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43) Goldberg A, Sherrard DJ, Brunzell JD: Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism. J Clin Endocrinol Metab, 1978; 47: 1173-1182","DOI":"10.1210\/jcem-47-6-1173"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44) Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest, 2003; 63: 45-53","DOI":"10.1080\/00365510310000484"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45) Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T: A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant, 2005; 20: 1172-1179","DOI":"10.1093\/ndt\/gfh774"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46) Dautin G, Soltani Z, Ducloux D, Gautier T, de Barros JPP, Gambert P, Lagrost L, Masson D: Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int, 2007; 72: 871-878","DOI":"10.1038\/sj.ki.5002449"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47) Shearer GC, Kaysen GA: Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int, 2006; 70: 647-653","DOI":"10.1038\/sj.ki.5000318"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48) Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol, 1997; 273: F925-F930","DOI":"10.1152\/ajprenal.1997.273.6.F925"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49) Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int, 1990; 37: 854-858","DOI":"10.1038\/ki.1990.58"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P900003-JLR200"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51) Kimak E, Solski J: ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail, 2002; 24: 485-492","DOI":"10.1081\/JDI-120006775"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52) Mekki K, Prost J, Remaoun M, Belleville J, Bouchenak M: Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients. BMC Cardiovasc Disord, 2009; 9: 41 citation=53) Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis, 1993; 21: 573-592","DOI":"10.1016\/S0272-6386(12)80030-8"},{"key":"52","doi-asserted-by":"crossref","unstructured":"54) Sato T, Liang KH, Vaziri ND: Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int, 2003; 64: 1780-1786","DOI":"10.1046\/j.1523-1755.2003.00281.x"},{"key":"53","doi-asserted-by":"crossref","unstructured":"55) Klin M, Smogorzewski M, Ni ZM, Zhang GX, Massry SG: Abnormalities in hepatic lipase in chronic renal failure - Role of excess parathyroid hormone. J Clin Investig, 1996; 97: 2167-2173 citation=56) Liang K, Vaziri ND: Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int, 1997; 51: 1933-1937","DOI":"10.1038\/ki.1997.263"},{"key":"54","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000154144.73236.f4"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00710-3"},{"key":"56","doi-asserted-by":"crossref","unstructured":"59) Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G: Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol, 2006; 97: 943-946","DOI":"10.1016\/j.amjcard.2005.10.062"},{"key":"57","unstructured":"60) Lamarche B, Lemieux I, Despres JP: The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab, 1999; 25: 199-211"},{"key":"58","doi-asserted-by":"crossref","unstructured":"61) Kim C, Vaziri ND: Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int, 2005; 67: 1028-1032","DOI":"10.1111\/j.1523-1755.2005.00166.x"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.03.015"},{"key":"60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.19.9252"},{"key":"61","doi-asserted-by":"crossref","unstructured":"64) Liang KH, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney International, 1998; 53: 626-630","DOI":"10.1046\/j.1523-1755.1998.00786.x"},{"key":"62","doi-asserted-by":"crossref","unstructured":"65) Liang K, Vaziri ND: Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrol Dial Transplant, 1997; 12: 1381-1386","DOI":"10.1093\/ndt\/12.7.1381"},{"key":"63","doi-asserted-by":"crossref","unstructured":"66) Vaziri ND, Liang KH: Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int, 1996; 50: 887-893","DOI":"10.1038\/ki.1996.388"},{"key":"64","doi-asserted-by":"crossref","unstructured":"67) Vaziri ND, Liang KH: Hepatic Hmg-Coa Reductase Gene-Expression During the Course of Puromycin-Induced Nephrosis. Kidney Int, 1995; 48: 1979-1985","DOI":"10.1038\/ki.1995.500"},{"key":"65","doi-asserted-by":"crossref","unstructured":"68) Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation, 2000; 102: 1082-1085","DOI":"10.1161\/01.CIR.102.10.1082"},{"key":"66","doi-asserted-by":"crossref","unstructured":"69) Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009; 302: 412-423","DOI":"10.1001\/jama.2009.1063"},{"key":"67","doi-asserted-by":"crossref","unstructured":"70) Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J: High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol, 2005; 16: 1794-1802","DOI":"10.1681\/ASN.2004110922"},{"key":"68","doi-asserted-by":"crossref","unstructured":"71) Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol, 2000; 11: 105-115","DOI":"10.1681\/ASN.V111105"},{"key":"69","doi-asserted-by":"publisher","DOI":"10.5551\/jat.10.283"},{"key":"70","doi-asserted-by":"crossref","unstructured":"73) de Sain-van der Velden MG, Reijngoud DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, Koomans HA, Rabelink TJ: Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol, 1998; 9: 1474-1481","DOI":"10.1681\/ASN.V981474"},{"key":"71","doi-asserted-by":"crossref","unstructured":"74) Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H: In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int, 2007; 71: 1036-1043","DOI":"10.1038\/sj.ki.5002131"},{"key":"72","doi-asserted-by":"crossref","unstructured":"75) Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant, 1999; 14: 1462-1466","DOI":"10.1093\/ndt\/14.6.1462"},{"key":"73","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000103624.14436.4B"},{"key":"74","doi-asserted-by":"publisher","DOI":"10.1021\/bi952242v"},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1038\/nature01250"},{"key":"76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197712222972502"},{"key":"77","doi-asserted-by":"crossref","unstructured":"80) Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D KM, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, for the Chronic Renal Insufficiency Cohort: Fibroblast Growth Factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol, 2012; 7: 1155-1162","DOI":"10.2215\/CJN.13281211"},{"key":"78","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000042700.48769.59"},{"key":"79","doi-asserted-by":"crossref","unstructured":"82) Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M: In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int, 2009; 76: 437-444 citation=83) Weichhart T, Kopecky C, Kubicek M, Haidinger M, Doller D, Katholnig K, Suarna C, Eller P, Tolle M, Gerner C, Zlabinger GJ, van der GM, Horl WH, Stocker R, Saemann MD: Serum Amyloid A in Uremic HDL Promotes Inflammation. J Am Soc Nephrol, 2012; 23: 934-947","DOI":"10.1681\/ASN.2011070668"},{"key":"80","doi-asserted-by":"crossref","unstructured":"84) Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res, 2009; 153: 77-85","DOI":"10.1016\/j.trsl.2008.11.007"},{"key":"81","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0245"},{"key":"82","doi-asserted-by":"crossref","unstructured":"86) Vaziri ND: Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr, 2010; 20: S35-S43","DOI":"10.1053\/j.jrn.2010.05.010"},{"key":"83","doi-asserted-by":"crossref","unstructured":"87) Bahlmann FH, Speer T, Fliser D: Endothelial progenitor cells in chronic kidney disease. Nephrology Dialysis Transplantation, 2010; 25: 341-346","DOI":"10.1093\/ndt\/gfp643"},{"key":"84","doi-asserted-by":"crossref","unstructured":"88) Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med, 2009; 360: 1395-1407","DOI":"10.1056\/NEJMoa0810177"},{"key":"85","doi-asserted-by":"crossref","unstructured":"89) Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005; 353: 238-248","DOI":"10.1056\/NEJMoa043545"},{"key":"86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13638-0"},{"key":"87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"88","doi-asserted-by":"crossref","unstructured":"92) Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267","DOI":"10.1056\/NEJMoa1107579"},{"key":"89","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"90","doi-asserted-by":"crossref","unstructured":"94) Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, Kreisberg R, Goldberg R: American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract, 2012; 18 Suppl 1: 1-78","DOI":"10.4158\/EP.18.S1.1"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T14:17:41Z","timestamp":1643552261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/20\/2\/20_12849\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.12849","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}